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Received 6 September 2007; received in revised form 16 September 2007; accepted 18 September 2007; Available online 3 December 2007AbstractObjective: The Maze procedure can restore sinus rhythm in patients suffering from chronic atrial fibrillation but often fails to restore the
mechanical function of the atrium, the so-called atrial kick and requires long-term anticoagulation most of the time. A micro motorless pump
(Atripump) based on artificial muscle technology positioned on the external surface of the atrium could compress the heart chamber, restoring
atrium transport function. A bench model reproducing the mechanical function of human atrium and human environment has been developed to
assess the circulatory support that such a pump can provide. Methods: Atripump (Nanopowers SA, Switzerland) is a dome-shape, silicone-coated
nitinol actuator to be sutured on the external surface of the atrium. A pacemaker-like control unit drives the actuator and manages the external
compression of the atrium. The bench model consists of an open circuit made of rubber bladder, 60 cc in volume, connected to a vertically
positioned and scaled tube that is filled at different levels reproducing changes in cardiac pre-load and after-load. The pump was placed on the
outer surface of the bladder and both were immersed in water having a constant temperature of 37 8C. Pressure, volume and temperature at the
interface dome—bladder were recorded. Results: Pump ran 24 h for three consecutive months. During the experiment, no technical failure
occurred and the pressure and volume values were repeatable during the experience. Nitinol fatigue was assessed measuring the wire’s electric
resistance that remained 400  10 V/m. Contraction rate was 1 Hz with power supply of 12 V, 400 m and heating time of 300 ms. Pre-load ranged
from 11 to 15 mmHg. When inserted in the bath at 37  0.5 8C, maximal temperature between silicone membrane and rubber bladder was 39 8C.
Maximal volume pumped was 492 ml/min. Conclusions: This artificial muscle pump can reproduce the mechanical effect of a normal human
atrium. It is compact, reliable and follows the Starling law. The surface temperature is in the physiologic range and it could represent a new tool to
restore the atrial kick in persistent atrial fibrillation.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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The atrium serves three major functions that affect
overall cardiac performances: it is a contractile chamber that
actively empties immediately before the ventricular systole
and establishes ventricular end diastolic volume, it is a
reservoir that stores venous return during systole and
isovolumic relaxation and it is a conduit that empties its
content into the ventricle down a pressure gradient after the
atrioventricular valve opens and continues to passively
transfer the blood during diastole. William Harvey first
described the contractile activity of the atrium in 1628 and
its contribution to cardiac performances [1]. This booster§ Presented at the 21st Annual Meeting of the European Association for
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to preserve cardiovascular performances in patients with
reduced ventricular functions. Loss of atrial contraction with
the onset of atrial fibrillation (AF) is commonly associated
with a reduction in cardiac output.
Chronic or persistent AF is the most frequent cardiac
arrhythmia in over fifties and is associated with structural
heart disease that could reduce the cardiac output up to 15%
[2—5]. Moreover, it is considered a risk factor for throm-
boembolic events because up to 5% of patients experience
one or more cerebrovascular accidents.
Therefore, AF causes a loss of quality of life (QOL) and a
significant threat of stroke with the ensuing effects. The
existing treatment consists primarily of palliation and is
based on drugs having a negative chronotrope effect, drugs
that reduce the risk of thromboembolic accidents and
endovascular or surgical procedures to restore the sinus
rhythm (Maze procedure). The Maze procedure was first
described by Cox in the early 1990s and is based on theSurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. The dome is made of nitinol fibers connected to a plastic ring and
covered with a double layer of silicone (hand hold). This dome is placed on the
external surface of the right atrium and restores the atrial kick.concept of isolating the regions of the right and left
atrium, where the foci triggering the AF are located,
using thermo or cryoablation either with percutaneous
access or open surgery [6—12]. Basically, this procedure ends
up with a compartmentalization of both atria creating a
labyrinth with blind alleys in which the amount of atrial
myocardium is insufficient to sustain multiple wavelets of
re-entry.
The Maze procedure has been reported as effective in
restoring sinus rhythm (95% of patients at 3 years follow-up
are free from AF), but the rate of restoring atrial contraction
varies from 21 to 75% [11]. The percentage of patients with
restored atrial contraction seems to differ with the etiology
of AF: more than 90% of the patients with isolated AF or an
atrial septal defect have restored atrial contraction, whereas
only between 21% and 90% of patients with mitral valve
disease have restored atrial contraction after the Maze
procedure [11,12]. Therefore, even if sinus rhythm is
restored, atria have definitively lost their capability to
coordinate their contraction in order to produce an efficient
transport function, thus the hemodynamic gain is negligible.
Patients continue to require anticoagulation therapy for their
lifetime and are exposed to the risk of hemorrhagic
complications as high as 1% per year.
An atrial assist device represents a new concept to treat
AF. It could restore the transport function of the atrium and
avoid the need of chronic anticoagulation therapy. Nano-
technology enables the construction of micro-actuators
where the movement, and therefore the work, is generated
by changing the molecular structure of the so-called smart
materials when a low voltage is applied to them or when they
are heated or cooled. A micro motorless pump based on
artificial muscle technology positioned on the external
surface of the atrium could compress the heart chamber
restoring the pump function of the atrium. The artificial
muscle technology could avoid the limitations of current
cardiac assist devices such as tubes piercing the skin, heavy
power supplies and the need of lifetime anticoagulation
therapy.
Because this is a totally new concept, the primary aim of
this study is to assess the hemodynamic performances of the
atrial assist device in a bench model.2. Methods
2.1. Device description
Atripump (Nanopowers SA, Lausanne, Switzerland) is a
dome-shape, silicone-coated nitinol actuator 5—10 mm high,
mounted on a plastic ring having a diameter ranging from 45
to 55 mm (Fig. 1). Nitinol is a shape memory alloy (SMA). This
material undergoes changes in shape and hardness when
heated or cooled, and does so with great force. SMAs belong
to a class of metal alloys displaying a property called shape
memory effect. The source of the shape memory effect is a
diffusionless phase transformation as a solid, in which atoms
move cooperatively, often by shear-like mechanisms. SMAs
have a uniform crystal structure that radically changes to a
different structure at a specific temperature. When the
memory alloy is below this transition temperature (marten-sitic state) it can be stretched and deformed without
permanent damage. After the alloy has been stretched, if it is
heated above its transition temperature (austenite state),
the alloy recovers to the un-stretched shape and completely
reverses the previous deformation [13].
When the nitinol wires are electrically heated they
reduce their length and pull down the apex of the dome
therefore causing a reduction of the dome concavity. This is
the hemodynamic equivalent of a systole. When the current
is cut off, the nitinol wires get back to their rest
temperature and elongate to their rest length. Therefore,
the dome recovers the initial concavity. This is the
hemodynamic equivalent of a diastole. The changes in
dome concavity result in volume displacement. This cycle is
controlled by a pacemaker-like unit that senses ventricular
activity and gives current to the wires following a dedicate
algorithm. The dome should be sutured onto the atrium’s
epicardium in order to provide the mechanical support to
the blood circulation.
2.2. Bench model
The bench model reproducing the hemodynamic char-
acteristics of the atrium of a healthy man consists of an open
circuit made of latex bladder 60 mm in diameter filled with
water at room temperature. The bladder is connected to a
vertically positioned graduate tube that is filled at different
levels (from 10 to 30 cm with respect to the dome level)
reproducing changes in cardiac pre-load. The Atripump is
placed on the outer surface of the bladder and activated at a
fix rate of 60/min. A temperature probe is placed in between
the inner silicone membrane and the latex bladder, right in
the middle of the dome where eight nitinol fibers cross each
other. The dome and the bladder are then immersed in a
water bath kept at 37 8C to reproduce the physiologic
environment (Fig. 2). The height of the water column with
the dome in the off position corresponds to the pre-load. The
height of the same column at the end of the dome’s
contraction corresponds to the after-load. Pressures are
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Fig. 2. The bench model. The dome (detail in the left low corner) is placed on
the outer surface of the rubber bladder that is connected to vertical and
graduate column water. A control unit activates the dome 60 times per minute
causing the water column to go up and down. Volume ejected per single
contraction is measured directly on the scaled column: 10 mm corresponds to
2 ml.
Fig. 3. The dome is placed underwater and bath temperature is kept at 37 8C
to mimic in vivo environment. Rubber bladder has been removed to show the
details. Water temperature is monitored by the probe A. Probe B monitors the
temperature between the dome and the rubber bladder. This temperature
corresponds to the temperature the cardiac cells are exposed to. All data are
gathered using a dedicate software and stored in the laptop.expressed in cmH2O. Volume ejected per single contraction
(VJ) is measured directly on the scaled column: 10 mm
corresponds to 2 ml. Because the contraction rate is 1 Hz, we
calculate the pump output per minute with the following
formula: pump output = VJ  60 ml/min. A temperature
probe is placed between the outer surface of the dome
and the bladder in order to measure the hypothetical
temperature on the atrium surface (Fig. 3). Data are
expressed as mean and standard deviation.3. Results
Pump ran 24 h for three consecutive months. During the
experiment, no technical failure occurred and the pressure
and volume values were repeatable during all the experi-
ence. Nitinol fatigue was assessed measuring the wire’s
electric resistance that remained 400  10 V/m. The con-
traction rate was 1 Hz with power supply of 12 V, 400 mA for
300 ms. Wire recovery time was 700 ms. Pre-load ranged
from 15 to 21 cmH2O. Volume ejected per single contraction
(per s) ranged from 2  0.5 ml (pre-load 15 cmH2O) to
8  0.5 ml (pre-load 21 cmH2O). Fig. 4 represents detailed
results. Maximal silicone membrane temperature was
55  2 8C when the dome was activated in air at room
temperature. When inserted in the bath at 37  0.5 8C, the
maximal temperature between silicone membrane and
rubber bladder temperature was 39  0.5 8C. The pump
produced a maximal work of 16  103 J. Maximal volume
pumped was 492 ml/min. Mean volume pumped was
120  10 ml/min with a pre-load of 15 cmH2O and
maximal after-load of 16.5  0.5 cmH2O; 210  10 ml/min
with a pre-load of 17 cmH2O and maximal after-load of
20.5  0.5 cmH2O; 362  15 ml/min with a pre-load of
19 cmH2O and maximal after-load of 25  0.5 cmH2O and
489  10 ml/min with a pre-load of 21 cmH2O and maximal
after-load of 27  0.5 cmH2O.4. Discussion
Atripump is a laboratory prototype of atrial assist device
based on smart materials technology for the surgical
treatment of chronic AF. An implantable battery, to be
charged transcutaneously, will power the system. Intrao-
peratively, Atripump will be wrapped over the right and left
atrium and connected to the battery and a control unit,
which can be set transcutaneously, according to the patient’s
need.
The concept of an atrial assist device is completely new
probably not because anyone has thought of it but because it
was not worth it to implant a conventional pump to just
restore the atrial kick. Standard cardiocirculatory pumps,
either pneumatic or magnetically suspended, are very
expensive, require major surgical procedures to be
implanted and require anticoagulation therapy as well.
The proposed technology is based on artificial muscle
concepts using shape memory alloy technology. The major
advantage of this technology is that the material itself is the
engine, exactly as it happens in real life with the skeletal
muscle, with a tremendous simplification of the engineering
process of any cardiac assist device. The advantages of nitinol
wire are well known since the early 1970s when the first
ventricular assist devices and artificial hearts were designed
[14]. However, at that time, contraction cycle, material
fatigue, heating and energy supply were the major limita-
tions to face and this project never went further.
More recently, Yambe and co-workers [15,16] have
developed a nitinol-based artificial muscle to be used as
VAD that can be activated at a frequency of 40 times per
minute, which represents an important improvement with
respect to first experimental data. Today’s nitinol alloys
provide a billion working cycles in bench models and that
should correspond to more than 10 years lifetime. These data
make us confident that the described device should last for a
few years before a break of nitinol fibers occurs.
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Fig. 4. Changing in pressures generated and volumes displaced in different
pre-load conditions are plotted. Each cycle is over 1 s. The pump seems to
follow the Starling law because the volume ejected increases when the pre-
load increases.Atripump working cycle corresponds to healthy adult
heart rate in rest condition. This is possible because the
nitinol fiber takes only 300 ms to reach its transitional
temperature when electrically heated and has 700 ms to cool
down. We believe that in the next prototype’s generation,
the maximal activation rate will go up to 80 cycle/min.
Ventricular activity triggers the contraction of the pump;
an electrode placed on the epicardium senses the electrical
activity of the right ventricle and informs the control unit:
100—200 ms after the QRS an electric signal from the control
unit activates the dome.
The Atripump is able to pump the same volume, if not
more, as a normal atrium in physiologic conditions. The work
of normal human atrium is 0.19 Nm that corresponds to
0.19 J. This is easily calculated assuming the minimal atrial
pressure is 8 mmHg, maximal 36 mmHg, volume ejected per
systole 80 ml, with the following formula: W = DP  DV. The
work the Atripump provides is one order of magnitude bigger
than necessary and the contraction of the dome is very
smooth. With a maximum output of about half a liter per
minute it clearly satisfies the hemodynamic needs. More
interestingly, it seems to follow the Starling law revealing a
response to pre-load increasing similarly to natural cardiac
muscles: in the experimental set-up, pre-load was increased
from 15 to 21 cmH2O producing the right shift of the
pressure/volume curb plotted in Fig. 4. This way of behaving
gets the nitinol wire closer to natural muscle than ever.
The heating issue has always been one of the major
limitations for human applications of nitinol actuators
because the transitional temperature used to be above
100 8C. Local and systemic effects of heat dissipation
associated to thermally powered LVAS implantation are well
known [17]. In an elegant study published in 1988, Emoto and
co-workers reported the effects on surrounding tissue [17].
Systemic (lungs, kidneys, blood tissue, coagulation process)
and local effects of 20 W heat dissipation were analyzed in
five calves. Conclusions were that heat promoted neointima
proliferation at the interface pump—blood flow and angio-
genesis was observed in the tissue capsula adjacent to the
heat-dissipating surface. However, no deleterious systemic
or local effects of 20 W heat dissipation were reported. Thetransitional temperature of the nitinol wire used in this
application is 70 8C. However, the amount of thermal energy
transferred to surrounding structures is very low as has been
demonstrated by the increase of the temperature between
the membrane and the bladder in wet environment. The heat
dissipates so quickly in a wet environment that the
temperature does not go over 39 8C. Moreover, in real life,
the atrium and the blood circulating in it will work as a heat
exchange keeping the membrane temperature in a range
compatible with human implantation. However, only long-
term animal studies will confirm the safeness of this device
with respect to the thermal injury of surrounding tissues.
Another concern is pressure-induced lesions on the
surface of the atrium. The pressure imposed by the dome
structure may result in functional obstruction of the
ramifications of the coronary vessels causing diffuse hypoxia
of the myocardium. In addition one may expect compression-
related cell degeneration or necrosis in the myocardium.
Once again, only long-term animal study will give an
appropriate answer to this question.
The pump’s design presented in this paper has been
developed for the right atrium and is not suitable for the
complex geometry of the left atrium. Oval and/or figure-of-
eight configurations should better match left atrium anatomy
without impairing the flow in pulmonary veins.
We are conscious that there are still several critical
issues deserving further experimental studies to be
addressed, but Atripump represents a new and superior
strategy in fully restoring the transport function while
maintaining the natural biological lining of blood exposed
surfaces. Its realization requires leading edge technological
innovation. However, upon realization, this may in future
avoid the need for drug therapy and complications due to
anticoagulation treatment and monitoring. With sufficient
longevity of the device this technology has the potential to
significantly reduce the treatment cost for atrial fibrillation
and opens new hopes to the treatment of end-stage cardiac
failure.
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Appendix A. Conference discussion
Dr C. Schlensak (Freiberg, Germany): It’s an innovative design. I wonder
how it will be able to be put into clinical practice. As I understood, you put that
device on top of the right atrial appendage. However, if you support the
contraction of the right atrial free wall, it will not increase the output of the
right atrium.
Secondly, what do you do about fibrillation? With the Maze procedure we
want to convert patients to a sinus rhythm in order to prevent thromboembolic
complications. What do you do about that?
Dr Tozzi: First of all, I’m sorry to disagree with you. I don’t know why you
say that we can put it just on the appendix. We can put this dome all around the
right atrium. For the left atriumwe are developing a figure-of-8 shape, another
shape in order to squeeze the atrium. It’s a very soft structure. You can adapt
the structure to what meets your needs. So I disagree with you. It’s not just the
right appendix.
For the second question, this device doesn’t contraindicate the Maze
procedure. You can do the Maze procedure to restore sinus rhythm, to have a
nice ECG, but basically, because of the Maze procedure, you are creating a
labyrinth in the right and left atrium. You just lose the contractile function. If
you are able to restore the pump, you can get rid of anticoagulation, becausethe reason why you keep the patient on anticoagulation after the Maze
procedure is because there is a recirculation of blood in the atria. If you use this
device, you don’t need anymore anticoagulation because it’s outside the heart
and it moves both chambers, atrial chambers, so basically you do not have the
recirculation.
Dr Schlensak: I’m very curious to see that in clinical practice.
Dr Tozzi: Me too.
Dr J. Horisberger (Lausanne, Switzerland): I understand that the nitinol
needs a high temperature in order to contract. Is this going to be a problem
when it’s implanted? You talk about 378 in the bath here.
Dr Tozzi: It’s a very tricky question, because one other point with this fiber
is that in order to getmovement, in order to have the actuator effect, you have
to heat the fiber up to 70 8C. 708 is not compatible with humans. I mean you
cannot put a device such as this in the body, because otherwise you risk cooking
the heart. This is the reason why we isolated the fibers with silicone, and we
tested them in the bath at 378, so in physiologic conditions. On top of this, we
should remember that the heart is a wonderful heat exchanger. It’s able to cool
down everything, of course everything that has a temperature above 378. So
preliminary results in the setup I showed you showed that the temperature on
the top of the dome is just 398, so 28more than physiologic conditions, which is
absolutely compatible with animal implantation. We just started the chronic
animal study this month, and I will love to show you the results of this chronic
animal study next year.
Dr J. Mueller (Berlin, Germany): I would like to talk about the temperature
problem. You mentioned that the rate you can create with this material is
60 bpm. If you go up to a higher rate, the power consumption goes up too.
Will this create more problems with the heat, with the temperature of the
device? I calculated the device would have power consumption of more than
5 W. That is a lot for this little device, so it will heat up dramatically. Do you
think the device will be able to pump with rates of 70 or 80 bpm or even higher
rates?
Dr Tozzi: Thank you for your two questions. The first one, we can go up to
80. We already have done this. But it’s not a matter of temperature, because
the working temperature is always 708 for these fibers, so no matter the
frequency, it keeps at 708. But I definitely agree with you that if you go up with
frequency, you need more energy. If you run your car at 180 km/h, you need
more fuel. Of course the battery that will drive this device is not as small as the
battery for pacemakers, because the amount of energy, as you just said, is two
orders of magnitude bigger than a pacemaker battery. But we already
identified special batteries that can run for at least 24 h, and they can be
recharged transcutaneously with the TETsystem. I don’t know if you remember
the LionHeart. A few years ago we implanted the LionHeart with a TETsystem.
Basically it’s the same concept.
Dr Mueller: You end up finally with a TET system. You will not be able to
implant a device the size of a pacemaker. This is impossible.
Dr Tozzi: You mean the volume of the battery?
Dr Mueller: Yes, because of the volume of the battery you need.
Dr Tozzi: The volume will be something around 250 cc, so a quarter of a
liter.
Dr Mueller: For how long?
Dr Tozzi: For 24, 36 h. And the TETsystem today is 2 by 2 cm. They are not
able to do this all over the world. We identified one company that is able to do
this, a small one. I would love to give you all the technical details on this.
